Straits Times Index
3,240.58 +49.87 (+1.56%) Nikkei
26,739.03 +336.19 (+1.27%) Hang Seng
20,717.24 +596.56 (+2.96%) FTSE 100
7,389.98 +87.24 (+1.19%) BTC-USD
29,025.28 -1,030.30 (-3.43%) CMC Crypto 200
646.20 -27.17 (-4.03%)
Humanigen, Inc. (HGEN)
| Previous close | 2.2400 |
| Open | 2.2400 |
| Bid | 2.1400 x 800 |
| Ask | 2.1500 x 1000 |
| Day's range | 2.0850 - 2.3300 |
| 52-week range | 1.6700 - 23.5300 |
| Volume | |
| Avg. volume | 1,563,956 |
| Market cap | 153.275M |
| Beta (5Y monthly) | -1.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Humanigen Reports First Quarter 2022 Financial Results
SHORT HILLS, N.J., May 05, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called "cytokine storm" with its lead drug candidate, lenzilumab (LENZ®), today provided a corporate update and reported financial results for the first quarter ended March 31, 2022.
- Business Wire
Humanigen Announces Participation and Presentation at Multiple Conferences in May
SHORT HILLS, N.J., May 04, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ announced today that management will present and participate at multiple investors conferences in May 2022. Details of the conferences are as follows:
- Business Wire
Humanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHS
SHORT HILLS, N. J., April 19, 2022--Humanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHS
